| AML patients enrolled |
51 |
|
2 |
4% |
49 |
96% |
|
| ineligible |
2 |
|
0 |
|
2 |
|
|
| Gender |
|
|
|
|
|
|
|
| Male |
27 |
55% |
2 |
100% |
25 |
53% |
0.495 |
| Female |
22 |
45% |
0 |
0% |
22 |
47% |
|
| Race |
|
|
|
|
|
|
|
| White |
36 |
80% |
1 |
50% |
35 |
81% |
0.364 |
| Black or African American |
6 |
13% |
0 |
0% |
6 |
14% |
1.000 |
| Asian |
2 |
4% |
0 |
0% |
2 |
5% |
1.000 |
| American Indian or Alaska Native |
1 |
2% |
1 |
50% |
0 |
0% |
0.044 |
| Unknown |
4 |
|
0 |
|
4 |
|
|
| Patients in First Relapse |
44 |
90% |
2 |
100% |
42 |
89% |
1.000 |
| Refractory to Re-induction |
5 |
100% |
- |
|
5 |
100% |
|
| Prior Hematopoietic Stem Cell Transplant |
4 |
8% |
0 |
0% |
4 |
9% |
1.000 |
| Age at study entry in years (median, range) |
14.1 |
1.4 - 23.0 |
15.1 |
10.6 - 19.6 |
14.1 |
1.4 - 23.0 |
0.419 |
| WBC (× 103/μl) (median, range) |
3.3 |
0.5 - 1400 |
1.65 |
1.5 - 1.8 |
3.6 |
0.5 - 1400 |
0.111 |
| Length of CR1 in days (median, range) (n=44) |
306 |
(35 - 2212) |
361.5 |
(213 - 510) |
306 |
(35 - 2212) |
0.955 |
| Cytogenetics |
|
|
|
|
|
|
|
| Normal |
8 |
20% |
1 |
50% |
7 |
18% |
0.364 |
| Inv(16) |
7 |
18% |
1 |
50% |
6 |
16% |
0.323 |
| t(8;21) |
4 |
10% |
0 |
0% |
4 |
11% |
1.000 |
| Monosomy 7 |
1 |
3% |
0 |
0% |
1 |
3% |
1.000 |
| Del7q |
1 |
3% |
0 |
0% |
1 |
3% |
1.000 |
| Del5q |
1 |
3% |
0 |
0% |
1 |
3% |
1.000 |
| 11q23 |
4 |
10% |
0 |
0% |
4 |
11% |
1.000 |
| t(6;9) |
1 |
3% |
0 |
0% |
1 |
3% |
1.000 |
| +8 |
4 |
10% |
0 |
0% |
4 |
11% |
1.000 |
| Other |
9 |
23% |
0 |
0% |
9 |
24% |
1.000 |
| Unknown |
9 |
|
0 |
|
9 |
|
|
